fosinopril

bgcolor="#ffffff" align="center" colspan="2"\| Fosinopril
gcolor="#ffffff" align="center" colspan="2"\| 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy] (4-phenylbutyl)phosphinyl]acetyl]-trans-L-proline
gcolor="#ffffff" align="center" colspan="2"\| Fosinoprilat
gcolor="#efefef" align="center" colspan="2"\| Data below refers to fosinopril unless indicated
gcolor="#efefef"\|Empirical formula	bgcolor="#dfefff"\|C₃₀H₄₆NO₇P
gcolor="#efefef"\|Molecular weight	bgcolor="#dfefff"\|562.7
gcolor="#efefef"\|Bioavailability (Oral)	bgcolor="#dfefff"\|36%
gcolor="#efefef"\|Metabolism	bgcolor="#dfefff"\|hepatic, GIT mucosa (to fosinoprilat)
gcolor="#efefef"\| Elimination half life (Oral)	bgcolor="#dfefff"\|11.5 hours (fosinoprilat)
gcolor="#efefef"\|Excretion	bgcolor="#dfefff"\|renal
gcolor="#efefef"\|Pregnancy category	bgcolor="#dfefff"\|D (Australia)

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of chronic heart failure. Fosinopril is the first and only phosphonate-containing ACE inhibitor marketed. It is marketed by Bristol-Myers Squibb under the trade name Monopril®.

Development

The development of fosinopril started from the observation of the hypotensive effects of phosphoramidon, an extract from the bacterium Streptomyces tanashiensis. Phosphoramidon was found to be a potent inhibitor of ACE. It was speculated that the phosphoramide moiety in the molecule was central to its inhibition of ACE. Further studies found that the phosphoramide moiety served the dual-purpose of interacting with the Zn²⁺ in ACE, as well as mimicking the transition-state of the natural substrate of ACE. These discoveries led to the attempt to develop a new group of ACE inhibitors which contained the phosphoramide moiety. The initial lead proved to be very potent but unstable at physiological pH. Later compounds would have a phosphanate moiety (being more stable) in place of the phosphoramide. The lessons learnt in the development of enalapril and later ACE inhibitors were applied to the design and eventually fosinoprilat was developed.

Fosinoprilat and Fosinopril

Fosinoprilat proved to have the same problem as enalaprilat and the other carboxylate-containing ACE inhibitors (namely poor oral bioavailability). The solution, fortunately, was very similar - the addition of a hydrophobic side-chain to modulate the ionisation characteristics of the molecule. Thus fosinopril was developed. Fosinopril is administered as a prodrug and is converted in vivo to the active form fosinoprilat.

<< Previous

Word Browser

Next >>

buster & glen
list of danish victoria cross recipients
list of fijian victoria cross recipients
list of german victoria cross recipients
list of indian victoria cross recipients
naomi shemer
eskimo (album)
list of irish victoria cross recipients
list of kenyan victoria cross recipients
list of nepalese victoria cross recipients
list of new zealander victoria cross recipients

list of newfoundlander victoria cross recipients
list of rhodesian victoria cross recipients
iwashimizu shrine
list of scottish victoria cross recipients
list of sikkimese victoria cross recipients
list of south african victoria cross recipients
mark of the mole
list of swedish victoria cross recipients
list of swiss victoria cross recipients
list of ukrainian victoria cross recipients
list of welsh victoria cross recipients

crown castle
list of west indian victoria cross recipients
list of victoria cross recipients of uncertain nationality
the tunes of two cities
list of persian war victoria cross recipients
list of taranaki maori war victoria cross recipients
list of third china war victoria cross recipients
sleyman i of rm
arikara
third period
intermission: extraneous music from the residents' mole show

list of umbeyla campaign victoria cross recipients
list of second afghan war victoria cross recipients
list of falklands war victoria cross recipients
list of korean war victoria cross recipients
list of vietnam war victoria cross recipients
list of malaysia indonesia confrontation victoria cross recipients
seizo fukumoto
list of network theory topics
quattro
norwegian defence force
the living bible